Ameriprise Financial Inc. Purchases 25,134 Shares of Qiagen (NYSE:QGEN)

Ameriprise Financial Inc. lifted its position in Qiagen (NYSE:QGEN - Free Report) by 66.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,026 shares of the company's stock after acquiring an additional 25,134 shares during the period. Ameriprise Financial Inc.'s holdings in Qiagen were worth $2,807,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of QGEN. Freestone Grove Partners LP bought a new position in Qiagen during the fourth quarter worth about $23,584,000. Rehmann Capital Advisory Group raised its position in shares of Qiagen by 35.7% during the fourth quarter. Rehmann Capital Advisory Group now owns 7,217 shares of the company's stock worth $321,000 after purchasing an additional 1,898 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Qiagen during the fourth quarter worth about $4,330,000. AQR Capital Management LLC lifted its holdings in shares of Qiagen by 40.9% during the 4th quarter. AQR Capital Management LLC now owns 105,303 shares of the company's stock valued at $4,689,000 after purchasing an additional 30,571 shares in the last quarter. Finally, Perbak Capital Partners LLP acquired a new position in shares of Qiagen in the 4th quarter valued at approximately $1,517,000. Institutional investors own 70.00% of the company's stock.

Qiagen Stock Up 0.3%

QGEN traded up $0.13 during trading hours on Friday, hitting $45.13. 2,518,914 shares of the company's stock were exchanged, compared to its average volume of 1,166,674. The stock has a market cap of $10.03 billion, a price-to-earnings ratio of 125.66, a PEG ratio of 2.39 and a beta of 0.67. Qiagen has a 1-year low of $37.63 and a 1-year high of $49.30. The stock's 50-day moving average is $41.70 and its two-hundred day moving average is $41.88. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. The company had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company's quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.44 EPS. Sell-side analysts predict that Qiagen will post 2.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on QGEN. Robert W. Baird raised their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Wall Street Zen upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Finally, UBS Group dropped their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $48.42.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.